Imugene Statistics
Total Valuation
Imugene has a market cap or net worth of AUD 246.36 million. The enterprise value is 228.37 million.
Market Cap | 246.36M |
Enterprise Value | 228.37M |
Important Dates
The next estimated earnings date is Wednesday, May 28, 2025.
Earnings Date | May 28, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Imugene has 7.47 billion shares outstanding. The number of shares has increased by 10.54% in one year.
Current Share Class | n/a |
Shares Outstanding | 7.47B |
Shares Change (YoY) | +10.54% |
Shares Change (QoQ) | +1.54% |
Owned by Insiders (%) | 11.90% |
Owned by Institutions (%) | 10.92% |
Float | 6.27B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 3.88 |
P/TBV Ratio | 8.20 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -1.77 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -2.24 |
Financial Position
The company has a current ratio of 3.08, with a Debt / Equity ratio of 0.25.
Current Ratio | 3.08 |
Quick Ratio | 1.96 |
Debt / Equity | 0.25 |
Debt / EBITDA | n/a |
Debt / FCF | -0.15 |
Interest Coverage | -403.24 |
Financial Efficiency
Return on equity (ROE) is -100.19% and return on invested capital (ROIC) is -53.79%.
Return on Equity (ROE) | -100.19% |
Return on Assets (ROA) | -42.92% |
Return on Invested Capital (ROIC) | -53.79% |
Return on Capital Employed (ROCE) | -127.75% |
Revenue Per Employee | -367,920 |
Profits Per Employee | -25.86M |
Employee Count | 5 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.57% in the last 52 weeks. The beta is 3.31, so Imugene's price volatility has been higher than the market average.
Beta (5Y) | 3.31 |
52-Week Price Change | -68.57% |
50-Day Moving Average | 0.04 |
200-Day Moving Average | 0.05 |
Relative Strength Index (RSI) | 43.17 |
Average Volume (20 Days) | 36,874,236 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Imugene had revenue of AUD -1.84 million and -129.30 million in losses. Loss per share was -0.02.
Revenue | -1.84M |
Gross Profit | -1.84M |
Operating Income | -120.64M |
Pretax Income | -129.30M |
Net Income | -129.30M |
EBITDA | -116.82M |
EBIT | -120.64M |
Loss Per Share | -0.02 |
Balance Sheet
The company has 33.74 million in cash and 15.76 million in debt, giving a net cash position of 17.99 million or 0.00 per share.
Cash & Cash Equivalents | 33.74M |
Total Debt | 15.76M |
Net Cash | 17.99M |
Net Cash Per Share | 0.00 |
Equity (Book Value) | 63.28M |
Book Value Per Share | 0.01 |
Working Capital | 55.11M |
Cash Flow
In the last 12 months, operating cash flow was -91.93 million and capital expenditures -10.11 million, giving a free cash flow of -102.04 million.
Operating Cash Flow | -91.93M |
Capital Expenditures | -10.11M |
Free Cash Flow | -102.04M |
FCF Per Share | -0.01 |
Margins
Gross Margin | n/a |
Operating Margin | 6,557.96% |
Pretax Margin | 7,028.94% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Imugene does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -10.54% |
Shareholder Yield | -10.54% |
Earnings Yield | -52.49% |
FCF Yield | -41.42% |
Stock Splits
The last stock split was on November 12, 2002. It was a reverse split with a ratio of 0.13333.
Last Split Date | Nov 12, 2002 |
Split Type | Reverse |
Split Ratio | 0.13333 |
Scores
Imugene has an Altman Z-Score of -1.35. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -1.35 |
Piotroski F-Score | n/a |